Unlocking the Brain.
Transforming Treatment.

We pioneer LAT1-enabled delivery to cross the blood-brain barrier and transform how medicine reaches the brain, opening new avenues for treating neurological diseases.

Connect with us

About Us

From Impossible to Accessible.
Redefining Brain Delivery, One Molecule at a Time.

Our Mission

To unlock the brain for life-saving medicines by engineering precision delivery across the blood-brain barrier, starting with rare diseases that have no other way in.

Our Mission

To unlock the brain for life-saving medicines by engineering precision delivery across the blood-brain barrier, starting with rare diseases that have no other way in.

Our Mission

To unlock the brain for life-saving medicines by engineering precision delivery across the blood-brain barrier, starting with rare diseases that have no other way in.

Our Vision

A future where the blood-brain barrier is no longer a barrier, enabling transformative therapies to reach the brain and change lives everywhere.

Our Vision

A future where the blood-brain barrier is no longer a barrier, enabling transformative therapies to reach the brain and change lives everywhere.

Our Vision

A future where the blood-brain barrier is no longer a barrier, enabling transformative therapies to reach the brain and change lives everywhere.

What We Do

Revolutionizing Drug Delivery:
The LAT1 Advantage for CNS Therapies

Our lead program features a brain-penetrant version of chenodeoxycholic acid (CDCA) designed specifically for cerebrotendinous xanthomatosis (CTX). This innovative approach addresses a critical need in the treatment of this rare neurodegenerative disease.

Unlocking the Brain

Targeted Access Through LAT1 Transporter Pathways

Our innovative approach enables precise, non-invasive delivery of therapeutics across the blood-brain barrier.

Unlocking the Brain

Targeted Access Through LAT1 Transporter Pathways

Our innovative approach enables precise, non-invasive delivery of therapeutics across the blood-brain barrier.

Unlocking the Brain

Targeted Access Through LAT1 Transporter Pathways

Our innovative approach enables precise, non-invasive delivery of therapeutics across the blood-brain barrier.

Non-Invasive Solutions

No Direct CNS Administration Required

Experience the benefits of drug delivery without the need for invasive procedures. 

Non-Invasive Solutions

No Direct CNS Administration Required

Experience the benefits of drug delivery without the need for invasive procedures. 

Non-Invasive Solutions

No Direct CNS Administration Required

Experience the benefits of drug delivery without the need for invasive procedures. 

Broad Utility

Compatible with Diverse Small Molecules

Our platform is designed to work with a variety of therapeutics, expanding treatment options. 

Broad Utility

Compatible with Diverse Small Molecules

Our platform is designed to work with a variety of therapeutics, expanding treatment options. 

Broad Utility

Compatible with Diverse Small Molecules

Our platform is designed to work with a variety of therapeutics, expanding treatment options. 

We’re not reinventing CDCA

We’re unlocking its full potential by delivering it where it was never able to go:

THE BRAIN

We’re not reinventing CDCA

We’re unlocking its full potential by delivering it where it was never able to go:

THE BRAIN

We’re not reinventing CDCA

We’re unlocking its full potential by delivering it where it was never able to go:

THE BRAIN

Direct Brain Delivery

Engineering Molecules, Transforming Brain Therapies

Engineering Molecules,
Transforming Brain Therapies

Our Approach

Engineered Stability:   Enhancing Drug Efficacy for Optimal CNS Delivery

Our innovative approach to strategic deuteration significantly enhances metabolic stability and extends therapeutic half-life. This ensures that drugs receive the necessary time and exposure to effectively target the brain, maximizing their therapeutic potential.

Our Lead Program

LAT1- Enabled CDCA for Treating Cerebrotendinous Xanthomatosis

Our lead program delivers a brain-penetrant form of CDCA to treat neurological symptoms of CTX — a rare neurodegenerative disease with no effective CNS therapies.